MicroRNA 21 (miR-21) and miR-181b couple with NFI-A to generate myeloid-derived suppressor cells and promote immunosuppression in late sepsis

Infection and Immunity

Volumn 82, Issue 9, 2014, Pages 3816-3825

  McClure, Clara ^a   Brudecki, Laura ^a   Ferguson, Donald A ^a   Yao, Zhi Q ^a   Moorman, Jonathan P ^a   McCall, Charles E ^b   Gazzar, Mohamed El ^a  

^a East Tennessee State University   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; BACTERIUM LIPOPOLYSACCHARIDE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MICRORNA; MICRORNA 181B; MICRORNA 21; NFI A PROTEIN; NUCLEAR FACTOR I; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM CULTURE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL ISOLATION; CELL MATURATION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPSIS; SUPPRESSOR CELL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELL DIFFERENTIATION; DENDRITIC CELLS; IMMUNOSUPPRESSION; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICRORNAS; MYELOID CELLS; NFI TRANSCRIPTION FACTORS; SEPSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84906070150     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01495-14     Document Type: Article

References (50)

1. Hotchkiss RS, Monneret G, Payen D. 2013. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 13:260-268. http://dx.doi.org/10.1016/S1473-3099(13)70001-X.
2. McCall CE, Yoza B, Liu T, El Gazzar M. 2010. Gene-specific epigenetic regulation in serious infections with systemic inflammation. J. Innate Immun. 2:395-405. http://dx.doi.org/10.1159/000314077.
3. Remick DG. 2007. Pathophysiology of sepsis. Am. J. Pathol. 170:1435-1444. http://dx.doi.org/10.2353/ajpath.2007.060872.
4. Shelley O, Murphy T, Paterson H, Mannick JA, Lederer JA. 2003. Interaction between the innate and adaptive immune systems is required to survive sepsis and control inflammation after injury. Shock 20:123-129. http://dx.doi.org/10.1097/01.shk.0000079426.52617.00.
5. Shubin NJ, Monaghan SF, Ayala A. 2011. Anti-inflammatory mechanisms of sepsis. Contrib. Microbiol. 17:108-124. http://dx.doi.org/10.1159/000324024.
6. Perl M, Chung CS, Garber M, Huang X, Ayala A. 2006. Contribution of anti-inflammatory/immune suppressive processes to the pathology of sepsis. Front. Biosci. 11:272-299. http://dx.doi.org/10.2741/1797.
7. Torgersen C, Moser P, Luckner G, Mayr V, Jochberger S, Hasibeder WR, Dunser MW. 2009. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth. Analg. 108:1841-1847. http://dx.doi.org/10.1213/ane.0b013e318195e11d.
8. Brudecki L, Ferguson DA, McCall CE, El Gazzar M. 2012. Myeloidderived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect. Immun. 80:2026-2034. http://dx.doi.org/10.1128/IAI.00239-12.
9. Cohen J, Opal S, Calandra T. 2012. Sepsis studies need new direction. Lancet Infect. Dis. 12:503-505. http://dx.doi.org/10.1016/S1473-3099(12) 70136-6.
10. Wenzel RP, Edmond MB. 2012. Septic shock-evaluating another failed treatment. N. Engl. J. Med. 366:2122-2124. http://dx.doi.org/10.1056/NEJMe1203412.
11. Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moreno C, Scumpia PO, Laface DM, Heyworth PG, Efron PA, Moldawer LL. 2011. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 17:281-292. http://dx.doi.org/10.1007/s00894-010-0723-7.
12. Gabrilovich DI, Nagaraj S. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174. http://dx.doi.org/10.1038/nri2506.
13. Ostrand-Rosenberg S, Sinha P. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182:4499-4506. http://dx.doi.org/10.4049/jimmunol.0802740.
14. Kong YY, Fuchsberger M, Xiang SD, Apostolopoulos V, Plebanski M. 2013. Myeloid derived suppressor cells and their role in diseases. Curr. Med. Chem. 20:1437-1444. http://dx.doi.org/10.2174/0929867311320110006.
15. Lees JR, Azimzadeh AM, Bromberg JS. 2011. Myeloid derived suppressor cells in transplantation. Curr. Opin. Immunol. 23:692-697. http://dx.doi.org/10.1016/j.coi.2011.07.004.
16. Condamine T, Gabrilovich DI. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32:19-25. http://dx.doi.org/10.1016/j.it.2010.10.002.
17. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166:678-689. http://dx.doi.org/10.4049/jimmunol.166.1.678.
18. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC. 2005. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65: 3044-30481.
19. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63:4441-4449.
20. Martire-Greco D, Landoni VI, Chiarella P, Rodriguez-Rodrigues N, Schierloh P, Rearte B, Isturiz MA, Fernandez GC. 2014. All-transretinoic acid improves immunocompetence in a murine model of lipopolysaccharide-induced immunosuppression. Clin. Sci. 126:355-365. http://dx.doi.org/10.1042/CS20130236.
21. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, O'Malley KA, Wynn JL, Antonenko S, Al-Quran SZ, Swan R, Chung CS, Atkinson MA, Ramphal R, Gabrilovich DI, Reeves WH, Ayala A, Phillips J, Laface D, Heyworth PG, Clare-Salzler M, Moldawer LL. 2007. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204:1463-1474. http://dx.doi.org/10.1084/jem.20062602.
22. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Muller M, Blander JM, Tacke F, Trautwein C. 2010. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med. 207:1453-1464. http://dx.doi.org/10.1084/jem.20091474.
23. O'Connell RM, Zhao JL, Rao DS. 2011. MicroRNA function in myeloid biology. Blood 118:2960-2969. http://dx.doi.org/10.1182/blood-2011-03-291971.
24. BelikoffB, Hatfield S, Sitkovsky M, Remick DG. 2011. Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice. Shock 35:382-387. http://dx.doi.org/10.1097/SHK.0b013e3182085f12.
25. Osuchowski MF, Welch K, Siddiqui J, Remick DG. 2006. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177:1967-1974. http://dx.doi.org/10.4049/jimmunol.177.3.1967.
26. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. 2002. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467. http://dx.doi.org/10.1097/00024382-200206000-00004.
27. Brudecki L, Ferguson DA, Yin D, Lesage GD, McCall CE, El Gazzar M. 2012. Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis. Infect. Immun. 80:602-611. http://dx.doi.org/10.1128/IAI.05480-11.
28. Mazuski JE, Sawyer RG, Nathens AB, DiPiro JT, Schein M, Kudsk KA, Yowler C. 2002. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg. Infect. 3:161-173. http://dx.doi.org/10.1089/109629602761624171.
29. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. 2005. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438:685-689. http://dx.doi.org/10.1038/nature04303.
30. Roy S, Sen CK. 2011. MiRNA in innate immune responses: novel players in wound inflammation. Physiol. Genomics. 43:557-565. http://dx.doi.org/10.1152/physiolgenomics.00160.2010.
31. Stenvang J, Lindow M, Kauppinen S. 2008. Targeting of microRNAs for therapeutics. Biochem. Soc. Trans. 36:1197-1200. http://dx.doi.org/10.1042/BST0361197.
32. Ling V, Luxenberg D, Wang J, Nickbarg E, Leenen PJ, Neben S, Kobayashi M. 1997. Structural identification of the hematopoietic progenitor antigen ER-MP12 as the vascular endothelial adhesion molecule PECAM-1 (CD31). Eur. J. Immunol. 27:509-514. http://dx.doi.org/10.1002/eji.1830270223.
33. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzoni I. 2005. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 123: 819-831. http://dx.doi.org/10.1016/j.cell.2005.09.023.
34. Rosa A, Ballarino M, Sorrentino A, Sthandier O, De Angelis FG, Marchioni M, Masella B, Guarini A, Fatica A, Peschle C, Bozzoni I. 2007. The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation. Proc. Natl. Acad. Sci. U. S. A. 104:19849-19854. http://dx.doi.org/10.1073/pnas.0706963104.
35. Cuenca AG, Moldawer LL. 2012. Myeloid-derived suppressor cells in sepsis: friend or foe? Intensive Care Med. 38:928-930. http://dx.doi.org/10.1007/s00134-012-2575-3.
36. Laslo P, Pongubala JM, Lancki DW, Singh H. 2008. Gene regulatory networks directing myeloid and lymphoid cell fates within the immune system. Semin. Immunol. 20:228-235. http://dx.doi.org/10.1016/j.smim.2008.08.003.
37. Tsitsiou E, Lindsay MA. 2009. microRNAs and the immune response. Curr. Opin. Pharmacol. 9:514-520. http://dx.doi.org/10.1016/j.coph.2009.05.003.
38. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD. 2008. MicroRNAs: new regulators of immune cell development and function. Nat. Immunol. 9:839-845. http://dx.doi.org/10.1038/ni.f.209.
39. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. 2010. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 10:111-122. http://dx.doi.org/10.1038/nri2708.
40. Kim VN, Han J, Siomi MC. 2009. Biogenesis of smallRNAsin animals. Nat. Rev. Mol. Cell. Biol. 10:126-139. http://dx.doi.org/10.1038/nrm2632.
41. Zardo G, CiolfiA, Vian L, Starnes LM, Billi M, Racanicchi S, Maresca C, Fazi F, Travaglini L, Noguera N, Mancini M, Nanni M, Cimino G, Lo-Coco F, Grignani F, Nervi C. 2012. Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood 119:4034-4046. http://dx.doi.org/10.1182/blood-2011-08-371344.
42. Ouellet S, Vigneault F, Lessard M, Leclerc S, Drouin R, Guerin SL. 2006. Transcriptional regulation of the cyclin-dependent kinase inhibitor 1A (p21) gene by NFI in proliferating human cells. Nucleic Acids Res. 34:6472-6487. http://dx.doi.org/10.1093/nar/gkl861.
43. Broxmeyer HE, Franklin DS, Cooper S, Hangoc G, Mantel C. 2012. Cyclin dependent kinase inhibitors differentially modulate synergistic cytokine responsiveness of hematopoietic progenitor cells. Stem Cells Dev. 21:1597-1603. http://dx.doi.org/10.1089/scd.2011.0476.
44. Zhao JL, Rao DS, Boldin MP, Taganov KD, O'Connell RM, Baltimore D. 2011. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc. Natl. Acad. Sci. U. S. A. 108:9184-9189. http://dx.doi.org/10.1073/pnas.1105398108.
45. BelikoffBG, Hatfield S, Georgiev P, Ohta A, Lukashev D, Buras JA, Remick DG, Sitkovsky M. 2011. A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J. Immunol. 186:2444-2453. http://dx.doi.org/10.4049/jimmunol.1001567.
46. Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith CM, Hotchkiss RS. 2010. Characterization and modulation of the immunosuppressive phase of sepsis. Infect. Immun. 78:1582-1592. http://dx.doi.org/10.1128/IAI.01213-09.
47. Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, Wang X, Wang J, Yu H, Cao X, Wang Q. 2012. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J. Immunol. 188:5500-5510. http://dx.doi.org/10.4049/jimmunol.1103505.
48. Derive M, Bouazza Y, Alauzet C, Gibot S. 2012. Myeloid-derived suppressor cells control microbial sepsis. Intensive Care Med. 38:1040-1049. http://dx.doi.org/10.1007/s00134-012-2574-4.
49. Kohanbash G, Okada H. 2012. MicroRNAs and STAT interplay. Semin. Cancer Biol. 22:70-75. http://dx.doi.org/10.1016/j.semcancer.2011.12.010.
50. Zhang H, Nguyen-Jackson H, Panopoulos AD, Li HS, Murray PJ, Watowich SS. 2010. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 116:2462-2471. http://dx.doi.org/10.1182/blood-2009-12-259630.